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Abstract.
Two ruthenium(III) complexes, namely trans-indazolium[tetrachlorobis(indazole)-
ruthenate(III)], Hlnd[Rulnd2C14] and trans-hrfidazolium[tetrachlorobis(idazole)-
ruthenate(III)], HIm[Rulm2C14] exhibit high anticancer activity in an autochthonous
colorectal carcinoma model in rats. Recently, it has been shown that both complexes bind
specifically to human serum apotransferrin and the resulting adducts have been studied
through spectroscopic and chromatographic techniques with the ultimate goal of preparing
adducts with good selectivity for cancer cells due to the fact that tumour cells express high
amounts oftransferrin receptors on their cell surface.
In order to investigate whether the cellular uptake of the complexes was mediated by
apotransferrin or transferrin, we compared the antiproliferative efficacy of
HInd[RuInd2C14] and HIm[Rulm2C14] with its apotransferrin- and transferrin-bound form
in the human colon cancer cell line SW707 using the microculture tetrazolium test (MTT).
Our results show that especially the transferrin-bound forms exhibit high antiproliferative
activity, which exceeds that of the free complex, indicating that this protein can act as a
carrier ofthe ruthenium complexes into the tumor cell.
Introduction
A number of Ru(III) complexes exhibit antitumour activity in animal models (Clarke,
1989). Keppler et al. have recently developed anticancer ruthenium(III) complexes with N-
* 1 Correspondence to F. Kratz, Tumour Biology Center, Clinical Research, Breisacher
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heterocycles, and, among these, the complexes with the ligands imidazole and indazole are







These two complexes show high antitumour activity against an autochthonous colorectal
cancer model in rats, a model which simulates the colon cancer of humans very well
(Berger et al., 1989). Furthermore, both complexes exhibit antiproliferative activity in two
human colon cancer cell lines (SW707 and SW948) (Galeano et al., 1992). Considering the
observed IC50 concentrations in vitro of 110 tg/ml for Hlnd[Rulnd2C14] and 250 tg/ml
for Hlm[Rulm2Cl4] in SW707 with respect to possible tissue levels in vivo, it can be
assumed from the dosage active in vivo of 13 mg/ml forHlnd[Rulnd2C14] and 7-10 mg/ml
for HIm[Rulm2C14] that levels as high as the IC50 value can be reached for a short period
oftime only or by tissue accumulation.
Since malignant cells have a high iron requirement and, consequently, a large number of
receptors for the iron(III)-transport protein transferfin, it has been suggested that the
accumulation of ruthenium(III) complexes in tumours might be mediated by this plasma
protein (Clarke, 1989). Indeed, it has been previously reported that transferrin is
responsible for the selective delivery of radioactive 67Ga(III) complexes to tumor tissues
(Ward and Taylor, 1988). The simaificance of cellular uptake of transferrin with respect to
various malignant diseases has been reviewed (Aulbert, 1986).
Hence, to obtain a deeper insight ofthe interactions of antitumour Ru(III) complexes with
serum proteins, we have recently investigated the reactions of Hlnd[Rulnd2C14] and
HIm[RuIm2C14] with human serum (Kratz et al., 1992 and 1993) and especially with
apotransferrin (Kratz et al., 1994a): Protein-binding is rapid for HInd[RuInd2C14] (3-4
minutes at T 37 C) but takes about 5 hours for HIm[Rulm2C14] the major amount
being bound to human serum albumin and a smaller fraction to human serum transferrin.
Both complexes bind specifically around the iron(III) binding sites of apotransferrin as
shown by circular dichroism spectroscopy. More precise information on the binding sites of
the complexes has been revealed by soaking experiments ofhuman apolactoferrin crystals
with the two Ru(III) complexes. Preliminary results of the subsequent X-ray structure
analyses have been reported (Kratz et al. 1994b) demonstrating that both complexes bind
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to the unoccupied binding site with the N-hteroyles remaining attached to the
ruthenium
Due to the protein-binding properties of these omplexes, we wanted to investigate
whether their ellular uptake was mediated by transferrin and therefore ompared the
antiprolifrative efficacy ofHInd[RuInd2Cl4] and HIm[RuIm2C14] with its apotransferrin-
and transferrin-bound form in the human colon cancer cell line SW707 using the
microCulture tetrazolium test (MTT). The results of these experiments are reported in this
communiation.
Materials and methods
Substances and equipment. The ruthenium(III) complexes were synthesized as described previously
(Keppler et al., 1989). For the cell culture experiments the pure complexes were dissolved in 0.9% saline
solution (c 200 lag/ml). Human serum apotransferrin (98%, crystalline, essentially iron free,MW 80,000)
(apoTf hereafter) and human serum transferrin (98%, crystalline, iron saturated, MW 80,000) were
purchased from Serva, Heidelberg and Sigma Chemical Company respectively.
Preparation of Hlnd[Rulnd2Cl4] and HIm[Rulm2Cl4] bound to apotransferrin and transferrin
respectively. In the cell culture experiments varying amounts of the complexes (2, 4 and 8 equivalents)
were bound to the proteins. The final concentration of the protein/complex solution was e 200 tg of
Ru(III)eomplex per ml.
In order to prepare 11.0 ml of the protein/complex solution with 2 equivalents of the complex, the
following procedure was followed: 5.5 ml of an aqueous solution ofthe Ru(III) complex with e 0.4 mg/ml
(prepared by stirring at 37 C in bidistilled H20 for 5-10 minutes) were added to a 5.5 ml solution of the
protein (150.0 mg of apotransferrin or transferrin dissolved in the following buffer: 0.2 M NaC1, 0.008 M
NaH2PO4, 0.05 M NaHCO3) and then stirred for 1 hour in the ease of HInd[RuInd2C14] (color of the
solution changes from brown to green) and for 12 hours in the ease of HIm[RuIm2C14] (color of the
solution changes from orange to dark red). For binding 4 and 8 equivalents of the complex, 75.0 or 37.5
mg of either apotransferrin or transferrin were used.
Previous HPLC studies and ultra,filtration experiments have demonstrated that no free complex is present
after the stated time periods (Kratz et al. 1992 and 1994). Thus, the protein/complex solutions were directly
employed for the cell culture experiments.
Apotransferrin or transferrin running as control were dissolved in the same buffer as above and then
diluted with bidistilled H20 (150.0, 75.0, or 37.5 mg protein dissolved in 5.5 ml buffer to which 5.5 ml
bidistilled. H20 were added).
Cell lines. For the in vitro experiments a human cancer cell line SW707 was used, which was derived from
patients with colorectal cancer and was provided by the Tumor Bank of the Institute of Experimental
Pathology, German Cancer Research Center (Heidelberg, FRG). SW707 is a cell line derived from well-
differentiated adenocarcinomas of the rectum with a modal chromosome number of 47. Microscopically,
SW707 showed no microvesicular bodies. The cell line was routinely checked for their mucus production to
exclude the possibility that fibroblasts had overgrown the carcinoma cells. Moreover, they were tested for
The manuscript giving details of the X-ray structure analysis is in preparation (Baker et al.)
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mycoplasma contamination and proved to be negative. The cell lines were grown as monolayer cultures in
MEM medium (Gibco) supplemented with 10% heat-inactivated (57 C, 40 .min) fetal calf serum,
streptomycin (100 tg/ml), penicillin (100 IU/ml) and L-glutamine (2 tmol/ml; all from Serva, Heidelberg,
FRG). The cells were maintained in a humified atmosphere (5% CO2/95% air) at 37 C.
MTT test. Monolayer cell cultures were trypsinised and single-cell suspensions were obtained by repeated
pipetting. The percentage of viability was determined by the trypan-blue exclusion test. A final
concentration of approximately 2 x 104 cells/ml medium was prepared, and then 1.0 ml was added to each
well of a 24-well culture plate. On the day following the plating; of cells, the test compounds were added at
the respective concentrations. The MTT assay was performed after the cells had been incubated with the
test substances for 3 consecutive days (days 2, 3 and 4).
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT; Sigma, FRG) was dissolved in
phosphate-buffered saline (Oxoid Ltd., Basingstoke, England) at 5 mg/ml and filtered through a 0.22-tm
Millipore filter, after which 100 tl of this MTT solution was added to each well (0.1 ml/ml medium). After
incubation of the plates with MTT for 1 h at 37 C, the medium was discarded and 500 tl acid-isopropanol
(0.2 ml 0.04N HC1 in 10 ml isopropanol) was added to all wells to stop the enzyme reaction. Within 1 h of
this addition the extinction of the colored formazon derivative dissolved in acid-isopropanol was
determined on a flow Flow Multiscan MC plate reader at a wavelength of 540 nm (reference wavelength:
690 nm).
At a given concentration, the MTT test was performend in 4 wells and the mean value calculated from
these experiments is presented in Figures 1 and 2. Standard deviations were below 15% and are not shown
in the figure.
Results
The results of our cell culture experiments are shown in Figures 1A and B for the
Hlnd[Rulnd2C14] series and in Figures 2A and B for the HIm[Rulm2C14] series. 2, 4 and 8
equivalents ofthe Ru(III) complex were bound to the proteins in order to establish whether
varying amounts of the bound complex had an effect on antiproliferative efficacy. The
extinction values are displayed as columns for days 2, 3, and 4, and the tested
concentrations were 100, 50 and 25 tg/ml ofthe free or protein-bound complex.
Figure 1A illustrates that the transferrin-bound forms ofHInd[Rulnd2C14] exhibit a strong
inhibitory effect at all of the concentrations tested when compared to the control and
exceeds that ofthe free complex at the low dose of25 tg/ml. By contrast, transferrin alone
exhibits a strong stimulatory effect at high concentrations, and this result was to be
expected considering that transferrin is an essential growth factor for cell culture.
The apotransferrin-bound form of HInd[RuInd2C14] is not as active as the transferrin-
bound form as can be seen in Figure lB. Also, the free complex exhibits a
strongerinhibitory effect than the apotransferrin-bound forms. Nevertheless, the protein-
bound form exhibits quite a strong inhibitory effect at the high concentration of 100 tg/ml
compared to the control and exceeds that of pure apotransferrin, which also shows an
inhibitory effect compared to the control.
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Figure 1A: Comparison of the inhibitory effect of the free complex HInd[RuInd2C14] and
its Fe(III)2-transferrin-bound forms in the human colon cancer cell line SW707 using the
microculture tetrazolium test (MTT).
Different amounts of I-IInd[RuInd2Cl4] (2,4 and 8 equivalents) were bound to Fe(III)2-transferrin. 100, 50,
25 represent 100, 50 or 25 g/ml of HInd[RuInd2Cl4]. Fe100, FeS0, Fe25 are comparative amounts of pure
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Figure IB: Comparison of the inhibitory effect of the frcc complex I-Hnd[-RuInd2Cl4] and
its apotransfcrrin-bound forms in the human colon cancer cell line SW707 using the
microculture tetrazolium test (MTT)
Different amounts of Hlnd[RuInd2Cl4] (2,4 and 8 equivalents) were bound to apotransferrin. 100, 50, 25
represent 100, 50 or 25 g/ml of HInd[RuInd2Cl4]. A100, AS0, A25 are comparative amounts of pure
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Figure 2A: Comparison ofthe inlfibitory effect ofthe free complex HIm[RuIm2Cl4] and its
Fe(lll)2-transferrin-botmd forms in the human colon cancer cell line SW707 using the
microculture tetrazolium test (MTT).
Different amounts of HIm[Rulm2Cl4] (2,4 and 8 equivalents) were bound to Fe(III)2-transferrin. 100, 50,
25 represent 100, 50 or 25 g/ml of HIm[Rulm2Cl4]. Fel00, Fe50, Fe25 are comparative amounts of pure
Fe(III)2-traasferrin corresponding to the amounts of the protein used to prepare the protein-bound forms of
HIm[Rulm2Cl4]
extinction
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Figure 2B: Comparison ofthe inhibitory effect ofthe free complex Hlm[Rttlm2Cl4] and its
apotransferrin-botmd forms in the human colon cancer cell line SW707 using the
microculture tetrazolium test (MTT).
Different amounts of HIm[Rulm2Cl4] (2,4 and 8 equivalents) Were bound to apotransferrin. I00, 50, 25
represent 100, 50 or 25 g/ml of HIm[Rulm2Cl4]. A100, A50, A25 are comparative amounts of pure
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In contrast, the apotransfrrin-bound forms of th scond complex, HIm[RuIm2C14]
xhibit a stronger inhibitory ffct than th fre complex, th protein-bound forms being
about twic as activ as th fr complex (Figure 2B). Similar rsultswr obtained for th
transfnn-bound form (Figur 2A), th protein-bound form bing two to thr tims mor
effective than the free complex. Surprisingly, transferrin on its own did not stimulate cell
growth in this experiment prhaps du to th less pronounced growth ofth tumor calls
which was slower than in the xpdmnts with HInd[RuInd2C14].
In both xpdmnts th amount of complex bound to th proteins (2, 4, or 8 quivalnts)
did not hav a significant ffect on antiprolifrativ fficacy.
Discussion
It has ben shown recently that the most promising antitumour Ru(III) complex,
HInd[RuInd2C14] which is far less toxic in long trm application than the imidazole
analogue, binds within a fw minutes to the srum proteins albumin and transferrin (Kratz
t al., 1992). This rsult suggests that apotransferdn or transfrdn could act as a natural
carder of th drug to the tumor tissues owing to the high affinity between this mtal
transport protein and the larg number oftransfrdn receptors on the sttrfac oftumor cells
[Brock, 1985). There is meanwhil a considerable amount of videnc available which
demonstrates hat tumours in animals and man exhibit a vry high, "parasitic" uptake of
iron(III) when they are fast growing. AulbCrt has reviewed th literature on this
phenomenon (Aulbert, 1986) and together with his investigations demonstrated that
turnout cells exhibit a high amount of transfrdn rcptors by which they sequester iron.
Especially fast growing tumour cells show a much higher uptake ofiron-transferrin than the
normal surrounding tissue ofth affected organ. For these reasons, it is therefore tmpting
to exploit th transferdn cycl as a "natural" rout for th sdectiv ddivry of cytostatic
drugs to cancer calls.
Transferrin is the iron-carrying protein in th serum of vertebrates. It is a -glycoprotein
with a molecular wight of 80 000 and is present in human serum at a concentration of 2.5-
3.5 mg/ml. The iron-free transfrdn is called apotransferrin and can bind two equivalents of
F(III) in th N- and C-trminal lobes of the protein upon which the protein undergoes a
conformational change.
When encountering the cell surface, iron-bound transferrin binds to a specific cell surface
receptor (transferrin receptor). The next step is intemalisation of the transferrin-receptor
complex by endocytosis, followed by removal of iron from transferrin with the aid of
intracellular chelates and involves fusion with endosomes, where the pH is lower (pH 5);
finally the apotransferrin is returned to the extracellular medium.
If the ruthenium complexes are being transported by transferrin or apotransferrin to the
tumour cells, they have to be released again to exert their antitumour effect after the
protein/complex-adduct has entered the tumour cell. The release should occur at low pH-
values (pH 5) with the aid of chelates. We have previously shown that both Ru(III)
complexes can be released tom apotransferrin or transferrin at pH 4-5 in the presence of
citric acid or ATP (Kratz et al., 1994), presumably in a form in which the chlorides of the
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original complex are substituted by citrate and ATP respectively, so that the cellular uptake
ofthe lu(IH) complexes could follow the transferrin path.
Our cell culture experiments demonstrate that the transfen-botmd forms of both
complexes exhibit high antiproliferative activity which even exceeds that of the free
complex.
The results for apotransferrin-bound forms, however, show a different picture: the
apotransferdn-botmd form of Hlnd[Rulnd2C14] is not as active as the respective free
complex, but the bound form of Hlm[Rulm2C14] is. This difference could possibly be
explained by the larger change in the protein conformation when HIm[Rulm2C14] binds to
apotransferfin due to the smaller N-heterocycle. This change in the conformation is then
similar to that that which takes place when iron(III) is bound then, so that the high affinity
between the transferrin receptor and transferrin-bound form ofthe complex is retained.
Although we have not demonstrated that the Ru(llI) complexes are released inside the cell,
the transferdn-bound forms of both complexes and the apotransferrin-botmd form of
Hlm[Rulm2Cl4] retain their antiproliferative effect. Our results therefore shed light on the
discrepancies observed between the in vitro IC50 values ofHInd[Rulnd2C14] (110 mg/ml)
and the dosages active in vivo (13.0 mg/kg). Tissue levels as high as the IC50 value can
only be reached for short periods of time at this in vivo dosage or by tissue accumulation
which could be achieved by transferrin acting as a carrier ofthe Ru(III) complex.
We are therefore planning animal experiments to strengthen our working hypothesis.
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